The approval granted by a DRA is limited in its scope to the national territory. An inventor who is granted a patent for a new and inventive drug may still be denied regulatory approval if clinical tests show potential negative effects of this drug on the human body. The originator of a drug thus has to file two separate applications, one with the DRA (for the regulatory approval) and another at the patent office (for the respective product and/or process patents).